The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Alvocidib plus cytarabine and mitoxantrone in MCL1-dependent R/R AML
In this interview, Tara Lin, MD, of the University of Kansas Medical Center, Kansas City, KS, discusses the results of the Phase II Zella 201 study (NCT02520011) evaluating the clinical response of alvocidib in combination with cytarabine and mitoxantrone (ACM) in MCL1-dependent, relapsed/refractory acute myeloid leukemia (AML) patients. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Lin discusses the clinical activity, particularly in those refractory to frontline therapy, of alvocidib given prior to cytarabine and mitoxantrone in MCL1-dependent AML.
